Bioavailability and Efficacy of a Gap Junction Enhancer (PQ7) in a Mouse Mammary Tumor Model

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Shishido, Stephanie N ^a   Prasain, Keshar ^a   Beck, Amanda ^a   Nguyen, Thi D T ^a   Hua, Duy H ^a   Nguyen, Thu Annelise ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CONNEXIN 43; GAP JUNCTION PROTEIN; PQ 7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CELL COMMUNICATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; FEMALE; HISTOPATHOLOGY; IMMUNOBLOTTING; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; TUMOR MODEL; TUMOR VOLUME;

AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GAP JUNCTIONS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; QUINOLINES;

ANIMALIA; MUS;

EID: 84878940498     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067174     Document Type: Article

References (33)

1. Wei CJ, Xu X, Lo CW, (2004) Connexins and cell signaling in development and disease. Annu Rev Cell Dev Biol 20: 811-838. doi:10.1146/annurev.cellbio.19.111301.144309. PubMed: 15473861.
2. Shi A, Nguyen TA, Battina SK, Rana S, Takemoto DJ, et al. (2008) Synthesis and anti-breast cancer activities of substituted quinolines. Bioorg Med Chem Lett 18: 3364-3368. doi:10.1016/j.bmcl.2008.04.024. PubMed: 18457950.
3. Gakhar G, Ohira T, Shi AB, Hua DH, Nguyen TA, (2008) Antitumor Effect of Substituted Quinolines in Breast Cancer Cells. Drug Dev Res 69: 526-534. doi:10.1002/ddr.20281.
4. Heiniger B, Gakhar G, Prasain K, Hua DH, Nguyen TA, (2010) Second-generation Substituted Quinolines as Anticancer Drugs for Breast Cancer. Anticancer Res 30: 3927-3932. PubMed: 21036704.
5. Ding Y, Prasain K, Nguyen TD, Hua DH, Nguyen TA, (2012) The effect of the PQ1 anti-breast cancer agent on normal tissues. Anticancer Drugs, 23: 897-905. PubMed: 22569107.
6. Shishido SN, Nguyen TA, (2012) Gap junction enhancer increases efficacy of Cisplatin to attenuate mammary tumor growth. PLOS ONE 7: e44963. doi:10.1371/journal.pone.0044963. PubMed: 23028705.
7. Guy CT, Cardiff RD, Muller WJ, (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961. PubMed: 1312220.
8. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, et al. (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163: 2113-2126. doi:10.1016/S0002-9440(10)63568-7. PubMed: 14578209.
9. Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, et al. (2001) Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 61: 8298-8305. PubMed: 11719463.
10. Banerjee D, Gakhar G, Madgwick D, Hurt A, Takemoto D, et al. (2010) A novel role of gap junction connexin46 protein to protect breast tumors from hypoxia. Int J Cancer 127: 839-848. PubMed: 20013805.
11. Lampe PD, Lau AF, (2004) The effects of connexin phosphorylation on gap junctional communication. Int J Biochem Cell Biol 36: 1171-1186. doi:10.1016/S1357-2725(03)00264-4. PubMed: 15109565.
12. Liu J, Ek Vitorin JF, Weintraub ST, Gu S, Shi Q, et al. (2011) Phosphorylation of connexin 50 by protein kinase A enhances gap junction and hemichannel function. J Biol Chem 286: 16914-16928. doi:10.1074/jbc.M111.218735. PubMed: 21454606.
13. Musil LS, Goodenough DA, (1991) Biochemical analysis of connexin43 intracellular transport, phosphorylation, and assembly into gap junctional plaques. J Cell Biol 115: 1357-1374. doi:10.1083/jcb.115.5.1357. PubMed: 1659577.
14. Hawat G, Baroudi G, (2008) Differential modulation of unapposed connexin 43 hemichannel electrical conductance by protein kinase C isoforms. Pflugers Arch 456: 519-527. doi:10.1007/s00424-007-0426-9. PubMed: 18172602.
15. Pitot HC, Dragan YP, (1994) The multistage nature of chemically induced hepatocarcinogenesis in the rat. Drug Metab Rev 26: 209-220. doi:10.3109/03602539409029792. PubMed: 8082566.
16. Budunova IV, Williams GM, (1994) Cell culture assays for chemicals with tumor-promoting or tumor-inhibiting activity based on the modulation of intercellular communication. Cell Biol Toxicol 10: 71-116. doi:10.1007/BF00756491. PubMed: 7953912.
17. Klaunig JE, Ruch RJ, (1990) Role of inhibition of intercellular communication in carcinogenesis. Lab Invest 62: 135-146. PubMed: 2406502.
18. Upham BL, Weis LM, Trosko JE, (1998) Modulated gap junctional intercellular communication as a biomarker of PAH epigenetic toxicity: structure-function relationship. Environ Health Perspect 106 Suppl 4: 975-981. doi:10.1289/ehp.98106s4975. PubMed: 9703481.
19. Rosenkranz HS, Pollack N, Cunningham AR, (2000) Exploring the relationship between the inhibition of gap junctional intercellular communication and other biological phenomena. Carcinogenesis 21: 1007-1011. doi:10.1093/carcin/21.5.1007. PubMed: 10783325.
20. Trosko JE, Ruch RJ, (1998) Cell-cell communication in carcinogenesis. Front Biosci 3: d208-d236. PubMed: 9458335.
21. Carystinos GD, Katabi MM, Laird DW, Galipeau J, Chan H, et al. (1999) Cyclic-AMP induction of gap junctional intercellular communication increases bystander effect in suicide gene therapy. Clin Cancer Res 5: 61-68. PubMed: 9918203.
22. Kunishige I, Samejima Y, Moriyama A, Saji F, Murata Y, (1998) cAMP stimulates the bystander effect in suicide gene therapy of human choriocarcinoma. Anticancer Res 18: 3411-3419. PubMed: 9858917.
23. Nagasawa H, Little JB, (1999) Unexpected sensitivity to the induction of mutations by very low doses of alpha-particle radiation: evidence for a bystander effect. Radiat Res 152: 552-557. doi:10.2307/3580153. PubMed: 10521933.
24. Park JY, Elshami AA, Amin K, Rizk N, Kaiser LR, et al. (1997) Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy. Gene Ther 4: 909-917. doi:10.1038/sj.gt.3300477. PubMed: 9349427.
25. Robe PA, Princen F, Martin D, Malgrange B, Stevenaert A, et al. (2000) Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ganciclovir gene therapy system: effects of dibutyryl adenosine 3',5'-cyclic monophosphate, alpha-glycyrrhetinic acid, and cytosine arabinoside. Biochem Pharmacol 60: 241-249. doi:10.1016/S0006-2952(00)00315-4. PubMed: 10825469.
26. Touraine RL, Vahanian N, Ramsey WJ, Blaese RM, (1998) Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum Gene Ther 9: 2385-2391. doi:10.1089/hum.1998.9.16-2385. PubMed: 9829537.
27. Zhou H, Randers-Pehrson G, Waldren CA, Vannais D, Hall EJ, et al. (2000) Induction of a bystander mutagenic effect of alpha particles in mammalian cells. Proc Natl Acad Sci U S A 97: 2099-2104. doi:10.1073/pnas.030420797. PubMed: 10681418.
28. Au JL, Jang SH, Zheng J, Chen CT, Song S, et al. (2001) Determinants of drug delivery and transport to solid tumors. J Control Release 74: 31-46. doi:10.1016/S0168-3659(01)00308-X. PubMed: 11489481.
29. Huang RP, Hossain MZ, Huang R, Gano J, Fan Y, et al. (2001) Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells. Int J Cancer 92: 130-138. doi:10.1002/1097-0215(200102)9999:9999. PubMed: 11279616.
30. Tanaka M, Grossman HB, (2001) Connexin 26 gene therapy of human bladder cancer: induction of growth suppression, apoptosis, and synergy with Cisplatin. Hum Gene Ther 12: 2225-2236. doi:10.1089/10430340152710568. PubMed: 11779406.
31. Burr DB, Molina SA, Banerjee D, Low DM, Takemoto DJ, (2011) Treatment with connexin 46 siRNA suppresses the growth of human Y79 retinoblastoma cell xenografts in vivo. Exp Eye Res 92: 251-259. doi:10.1016/j.exer.2011.02.003. PubMed: 21320488.
32. Mesnil M, Crespin S, Avanzo JL, Zaidan-Dagli ML, (2005) Defective gap junctional intercellular communication in the carcinogenic process. Biochim Biophys Acta 1719: 125-145. doi:10.1016/j.bbamem.2005.11.004. PubMed: 16359943.
33. Saunders MM, Seraj MJ, Li Z, Zhou Z, Winter CR, et al. (2001) Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res 61: 1765-1767. PubMed: 11280719.